Sign in
PRVB Stock Price, Chart, Stats & News
Provention Bio, Inc.
Save
2.38B
Market cap
–
Current P/E
–
Forward P/E
PRVB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 96.03% |
Operating margin | -993.88% |
Pretax margin | -984.54% |
Net margin | -880.69% |
Effective tax rate | 10.55% |
ROA | -47.95% |
ROE | 133.43% |
D/E | 0.20x |
Interest coverage ratio | -123.59x |
PRVB valuation
P/E | – |
P/S | 184.21x |
P/B | 15.32x |
P/CF | -24.75x |
P/FCF | -31.17x |
P/OCF | -24.75x |
PEG | -0.16x |
EV multiple | -19.21x |
About
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus.
Similar securities
Based on sector and market capitalization
Report issue